Squarepoint Ops LLC Acquires 53,807 Shares of Omnicell, Inc. $OMCL

Squarepoint Ops LLC raised its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 80.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 120,419 shares of the company’s stock after buying an additional 53,807 shares during the period. Squarepoint Ops LLC’s holdings in Omnicell were worth $5,000,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Dana Investment Advisors Inc. purchased a new stake in shares of Omnicell in the 4th quarter worth $3,445,000. Bank of America Corp DE lifted its position in Omnicell by 31.3% during the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new stake in Omnicell during the fourth quarter valued at about $2,022,000. BlackRock Inc. bought a new stake in Omnicell during the second quarter valued at about $313,044,000. Finally, Dimensional Fund Advisors LP grew its holdings in Omnicell by 6.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Zacks Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Finally, KeyCorp reissued an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Trading Up 1.7%

OMCL stock opened at $32.79 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell, Inc. has a 1-year low of $29.06 and a 1-year high of $55.00. The business has a 50 day simple moving average of $38.47 and a two-hundred day simple moving average of $39.07. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of 39.04, a PEG ratio of 0.81 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. During the same quarter in the previous year, the company earned $0.45 EPS. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.